A Phase 1b/2a, MultiCenter, Open- Label Study of Pocenbrodib as Monotherapy or in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs Abiraterone acetate (Primary) ; Olaparib (Primary) ; Pocenbrodib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pathos
- 29 Jan 2025 Planned initiation date changed from 15 Jan 2025 to 7 Feb 2025.
- 24 Jan 2025 New trial record